MiMedx Group (NASDAQ:MDXG) Sets New 52-Week Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.70 and last traded at $4.82, with a volume of 676785 shares. The stock had previously closed at $4.76.

Analyst Ratings Changes

MDXG has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. UBS Group set a $10.00 price objective on shares of MiMedx Group in a report on Monday, February 23rd. Citigroup started coverage on MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating on the stock. Citizens Jmp started coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price target for the company. Finally, Cantor Fitzgerald reduced their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Up 1.3%

The firm has a 50-day moving average of $5.56 and a two-hundred day moving average of $6.52. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $716.11 million, a PE ratio of 15.06 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The company had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. Equities research analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently made changes to their positions in MDXG. CWM LLC increased its position in shares of MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of MiMedx Group by 1,808.4% during the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in MiMedx Group in the fourth quarter valued at $48,000. State of Alaska Department of Revenue acquired a new stake in MiMedx Group in the third quarter valued at $54,000. Finally, Headlands Technologies LLC acquired a new stake in MiMedx Group in the second quarter valued at $72,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.